Treatment of SLE with anti-CD19 CAR-T cellsdoi:10.1038/s41581-022-00651-3Ellen F. CarneyNature Reviews NephrologyNature Publishing Group UKNature Reviews Nephrology
A Phase I Clinical Trial of Treatment of B-Cell Malignancies with Autologous Anti-CD19-CAR-Transduced T Cells Engineered artificial antigen-presenting cells provide a defined system for the rapid expansion of cytotoxic T cells used in adoptive immunotherapy. JN Kochenderfer,ME Dudley,Maryalice Stetler...
27 Overall, results from these clinical trials of anti-CD19 CARs for CLL demonstrated significant anti-leukemia activity; however, CR rates and PFSs are lower than the results obtained treating B-cell lymphoma with anti-CD19 CAR T cells,13,14,28 so there is room for improvement in anti-CD...
Interest in biological therapy for cancer has surged due to its precise targeting of cancer cells and minimized impact on surrounding healthy tissues. This
Administration for the treatment of four autoimmune indications, including SLE. IASO Bio will continue to collaborate with our peers to further promote innovation and development in the treatment of autoimmune diseases, so as to bring significant clinical benefits to patients through innovative therapies....
In recent years, a popular view of the pathogenesis of autoimmune disorders has been that B-cell derived events are ancillary to a basic breakdown in T-cell tolerance, and that although autoantibodies are present, the effector function of T cells is the fundamental pathological component. However...
proliferation of effector cells at the tumor sites. We next evaluated the adverse events associated with anti-CD19 CAR-T treatment. Patient 1 only showed grade 1 anemia and grade 4 lymphopenia on day 3 after infusion (TableS2). She didn’t complain of any discomfort post CAR-T therapy. ...
Here, we describe the successful immunotherapy and striking clinical improvement of two patients with severe concomitant MG and LEMS using autologous anti-CD19 CAR T cells. Results Patient history—Case 1 Patient 1, a 33-year-old woman, was first diagnosed with concomitant MG and LEMS in 2019....
Chimeric antigen receptor (CAR)-T cell therapy is a promising new treatment for cancer that involves genetically modifying a patient’s T-cells to rec
Adults with T cell leukaemias and lymphomas, collectively called T cell cancers, have short survival10,11 and lack such targeted therapies. Thus, T cell cancers particularly warrant the development of CAR T cells and antibodies to improve patient outcomes. Preclinical studies showed that targeting T...